Losartan Potassium Tablets, 100 Mg Tablet
Product Images NDC 72162-1698

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium Tablets, 100 Mg (NDC 72162-1698). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Figure1)

A line graph comparing the percentage of patients with the primary endpoint over 66 months in a study. It shows two lines representing Atenolol (dotted line) and Losartan Potassium (solid line), with Losartan Potassium demonstrating a lower percentage over time. The graph includes an adjusted risk reduction of 13% with a p-value of 0.021, and the x-axis labeled as Study Month.*

FDA Label Image

Figure 2 (Figure2)

A line chart comparing the percentage of patients with fatal/non-fatal stroke over 66 months in a study. It shows two lines: a dotted line for Atenolol and a solid line for Losartan Potassium. The graph indicates a lower stroke incidence with Losartan Potassium and notes an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Figure 3 (Figure3)

This image contains two forest plots comparing the primary endpoint events in demographic subgroups between Losartan and Atenolol. The left plot shows primary composite event rates and hazard ratios, and the right plot shows stroke event rates and hazard ratios, each stratified by age, gender, race, ischemic heart status, diabetes, and cardiovascular history. Symbols and hazard ratio confidence intervals indicate statistical comparisons favoring Losartan or Atenolol.*

FDA Label Image

Figure 4.jpg (Figure4)

A line chart comparing the percentage of patients with events over 48 months between two groups: Losartan Potassium and Placebo. The chart indicates a risk reduction of 16.1% with Losartan Potassium, showing a lower event rate compared to Placebo over time.*

FDA Label Image

Label (Lbl721621698)

This is a label for Losartan Potassium Tablets, USP 100 mg, relabeled by Bryant Ranch Prepack, Inc., and manufactured by Jubilant Cadista Pharmaceuticals Inc. The label indicates the product contains 1000 tablets and provides storage instructions to keep at 25°C with permitted excursions. It also includes a barcode and the NDC 72162-1698-0.*

FDA Label Image

Losartan Potassium, Usp (Structure)

Chemical structure diagram of losartan potassium, the active ingredient in Losartan potassium Tablets 100 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.